<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Access Archives - Myeloma Patients Europe</title>
	<atom:link href="https://www.mpeurope.org/category/access/feed/" rel="self" type="application/rss+xml" />
	<link>https://www.mpeurope.org/category/access/</link>
	<description></description>
	<lastBuildDate>Tue, 27 Oct 2026 10:49:05 +0000</lastBuildDate>
	<language>en-GB</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.1.4</generator>

<image>
	<url>https://www.mpeurope.org/wp-content/uploads/2023/07/logo_MPE-fav-1-150x150.png</url>
	<title>Access Archives - Myeloma Patients Europe</title>
	<link>https://www.mpeurope.org/category/access/</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>EMA committee recommends new talquetamab treatment combinations for relapsed or refractory myeloma</title>
		<link>https://www.mpeurope.org/ema-committee-recommends-new-talquetamab-treatment-combinations-for-relapsed-or-refractory-myeloma/</link>
					<comments>https://www.mpeurope.org/ema-committee-recommends-new-talquetamab-treatment-combinations-for-relapsed-or-refractory-myeloma/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Tue, 27 Oct 2026 10:49:05 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=117507</guid>

					<description><![CDATA[<p>On 15 October 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of talquetamab (Talvey®) to include combinations with daratumumab, either alone or together with pomalidomide, for myeloma patients who have received at least one previous line of treatment. The CHMP is the European Medicines Agency&#8217;s (EMA) committee responsible&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/ema-committee-recommends-new-talquetamab-treatment-combinations-for-relapsed-or-refractory-myeloma/">EMA committee recommends new talquetamab treatment combinations for relapsed or refractory myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="117507" class="elementor elementor-117507" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-750a021 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="750a021" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-bcb7b42" data-id="bcb7b42" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-e094e35 elementor-widget elementor-widget-text-editor" data-id="e094e35" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>On 15 October 2026, the <a href="https://www.ema.europa.eu/mt/node/288170" target="_blank" rel="noopener">Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of talquetamab (Talvey®)</a> to include combinations with <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/daratumumab/">daratumumab</a>, either alone or together with pomalidomide, for <a href="https://www.mpeurope.org/about-myeloma/what-is-myeloma/">myeloma</a> patients who have received at least one previous line of treatment.</p><p>The CHMP is the <a href="https://www.ema.europa.eu/en/homepage" target="_blank" rel="noopener">European Medicines Agency&#8217;s (EMA)</a> committee responsible for evaluating medicines and recommending whether medicines should be approved in the European Union. A positive recommendation from the CHMP still requires formal approval by the European Commission before it can be implemented. This process typically takes a few months.</p><p><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/talquetamab/" target="_blank" rel="noopener">Talquetamab</a> is a targeted immunotherapy that binds to the GPRC5D protein on myeloma cells and helps the immune system’s T cells to recognise and kill myeloma cells.</p><p>The CHMP recommendation is based on the results of the phase III MonumenTAL-3 study, published in the <a href="https://www.nejm.org/doi/10.1056/NEJMoa2604657">New England Journal of Medicine</a>. The study showed that patients treated with talquetamab plus daratumumab, with or without pomalidomide, lived longer without their myeloma getting worse than patients treated with daratumumab, pomalidomide and dexamethasone. Click <a href="https://www.youtube.com/watch?v=cPjVICdfMU0&amp;t=102s" target="_blank" rel="noopener">here</a> to watch a patient-friendly video explaining the study, its results and what they could mean for myeloma patients.</p><p>Talquetamab is <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/talvey" target="_blank" rel="noopener">currently authorised as monotherapy</a> (on its own) for myeloma patients who have received at least three previous treatments, including an immunomodulatory agent (e.g. lenalidomide or pomalidomide), a proteasome inhibitor (e.g. bortezomib or carfilzomib), and an anti-CD38 monoclonal antibody (e.g. daratumumab or isatuximab), and whose disease has worsened despite their most recent treatment.</p><p>It would also mark the first time a GPRC5D-targeting bispecific antibody could be used as a second-line myeloma treatment in the European Union.</p><p>Following European Commission approval, treatment availability will depend on pricing, reimbursement and access decisions in individual European countries.</p><p> </p><p> </p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/ema-committee-recommends-new-talquetamab-treatment-combinations-for-relapsed-or-refractory-myeloma/">EMA committee recommends new talquetamab treatment combinations for relapsed or refractory myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/ema-committee-recommends-new-talquetamab-treatment-combinations-for-relapsed-or-refractory-myeloma/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>EMA committee recommends melflufen label expansion to third-line myeloma treatment</title>
		<link>https://www.mpeurope.org/ema-committee-recommends-melflufen-label-expansion-to-third-line-myeloma-treatment/</link>
					<comments>https://www.mpeurope.org/ema-committee-recommends-melflufen-label-expansion-to-third-line-myeloma-treatment/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Tue, 22 Sep 2026 08:00:40 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=117103</guid>

					<description><![CDATA[<p>On September 17, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of melphalan flufenamide (melflufen, Pepaxti®) to third-line myeloma treatment. The CHMP is the European Medicines Agency’s (EMA) committee responsible for evaluating medicines and making recommendations on whether they should be approved for use&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/ema-committee-recommends-melflufen-label-expansion-to-third-line-myeloma-treatment/">EMA committee recommends melflufen label expansion to third-line myeloma treatment</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="117103" class="elementor elementor-117103" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-313c2a9 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="313c2a9" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-8843afd" data-id="8843afd" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-1ef1437 elementor-widget elementor-widget-text-editor" data-id="1ef1437" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>On September 17, 2026, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of melphalan flufenamide (melflufen, Pepaxti®) to third-line myeloma treatment.</p><p>The CHMP is the <a href="https://www.ema.europa.eu/en/homepage" target="_blank" rel="noopener">European Medicines Agency’s (EMA)</a> committee responsible for evaluating medicines and making recommendations on whether they should be approved for use in the European Union (EU). A positive recommendation from the CHMP still requires formal approval by the European Commission before it can be implemented, a process that typically takes a few months.</p><p><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/melphalan-flufenamide/">Melflufen</a> is a medicine called a peptide drug conjugate. It is designed to deliver the active chemotherapy agent melphalan into myeloma cells, where it helps damage and kill them.</p>								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-8d9f148" data-id="8d9f148" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-8097c89 elementor-widget elementor-widget-image" data-id="8097c89" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" src="https://www.mpeurope.org/wp-content/uploads/elementor/thumbs/EMAs-CHMP-positive-opinion-image-rtrsa6u7lce4ordewq9c5un2g6yfcikbszaed1qzr2.png" title="EMAs CHMP positive opinion image" alt="EMAs CHMP positive opinion image" loading="lazy" />															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-23df445 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="23df445" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-8088232" data-id="8088232" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-ae1b5bf elementor-widget elementor-widget-text-editor" data-id="ae1b5bf" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>The CHMP recommendation would allow melflufen, in combination with dexamethasone, to be used in myeloma patients who have received at least two prior lines of therapy and whose disease is refractory to lenalidomide and their last line of treatment.</p><p>Melflufen is currently <a href="https://www.ema.europa.eu/en/medicines/human/EPAR/pepaxti">authorised</a> in the EU for myeloma patients who have received at least three prior lines and whose disease is refractory to a proteasome inhibitor (e.g. bortezomib or carfilzomib), an immunomodulatory agent (e.g. lenalidomide or pomalidomide) and an anti-CD38 monoclonal antibody (e.g. daratumumab or isatuximab).</p><p>The recommendation is based on data from the phase 3 OCEAN trial. This study showed that melflufen plus dexamethasone delayed myeloma progression compared with pomalidomide plus dexamethasone, although it did not significantly improve overall survival in the overall trial population.</p><p>If approved, this would provide another treatment option for third-line myeloma patients in the EU. Following European Commission approval, treatment availability will depend on pricing, reimbursement and access decisions in individual European countries.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/ema-committee-recommends-melflufen-label-expansion-to-third-line-myeloma-treatment/">EMA committee recommends melflufen label expansion to third-line myeloma treatment</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/ema-committee-recommends-melflufen-label-expansion-to-third-line-myeloma-treatment/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myeloma</title>
		<link>https://www.mpeurope.org/ema-committee-recommends-teclistamab-plus-daratumumab-for-relapsed-or-refractory-multiple-myeloma/</link>
					<comments>https://www.mpeurope.org/ema-committee-recommends-teclistamab-plus-daratumumab-for-relapsed-or-refractory-multiple-myeloma/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Fri, 03 Jul 2026 12:28:59 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<category><![CDATA[Myeloma]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=116472</guid>

					<description><![CDATA[<p>On 25 June 2026, the Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®) to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy. The CHMP is the European Medicines Agency&#8217;s (EMA) committee responsible for&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/ema-committee-recommends-teclistamab-plus-daratumumab-for-relapsed-or-refractory-multiple-myeloma/">EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="116472" class="elementor elementor-116472" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-e8eae53 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="e8eae53" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-9e43c64" data-id="9e43c64" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-af49605 elementor-widget elementor-widget-text-editor" data-id="af49605" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>On 25 June 2026, the <a href="https://www.ema.europa.eu/en/medicines/human/variation/tecvayli" target="_blank" rel="noopener">Committee for Medicinal Products for Human Use (CHMP) recommended extending the approved use of teclistamab (Tecvayli®)</a> to include its use in combination with daratumumab for adults with relapsed or refractory myeloma who have received at least one prior therapy.</p><p>The CHMP is the <a href="https://www.ema.europa.eu/en/homepage" target="_blank" rel="noopener">European Medicines Agency&#8217;s (EMA)</a> committee responsible for evaluating medicines and making recommendations on whether they should be approved for use in the European Union. A positive recommendation from the CHMP still requires formal approval by the European Commission before it can be implemented, a process that typically takes a few months.</p><p><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/teclistamab/">Teclistamab</a> is a bispecific antibody that helps the immune system recognise and destroy myeloma cells.</p><p>The CHMP recommendation is based on the results of the phase III MajesTEC-3 study, published in the <a href="https://www.nejm.org/doi/full/10.1056/NEJMoa2514663" target="_blank" rel="noopener">New England Journal of Medicine</a>. The study showed that patients treated with the combination of teclistamab and daratumumab lived longer without their myeloma getting worse compared with those receiving standard treatment. Watch below a patient-friendly video explaining the study, its results and its implications for clinical practice.</p>								</div>
				</div>
				<div class="elementor-element elementor-element-6c7b8dc elementor-widget elementor-widget-spacer" data-id="6c7b8dc" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-bb52b7b elementor-widget elementor-widget-video" data-id="bb52b7b" data-element_type="widget" data-e-type="widget" data-settings="{&quot;youtube_url&quot;:&quot;https:\/\/www.youtube.com\/watch?v=LEFWII_tnsc&quot;,&quot;video_type&quot;:&quot;youtube&quot;,&quot;controls&quot;:&quot;yes&quot;}" data-widget_type="video.default">
				<div class="elementor-widget-container">
							<div class="elementor-wrapper elementor-open-inline">
			<div class="elementor-video"></div>		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-d6122e5 elementor-widget elementor-widget-spacer" data-id="d6122e5" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-9af706e elementor-widget elementor-widget-text-editor" data-id="9af706e" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>If approved, this would be the first authorised treatment combination in the European Union to combine a bispecific antibody with daratumumab for the treatment of myeloma.</p><p>Following any European Commission approval, availability will also depend on national assessment, pricing and reimbursement decisions in individual European countries.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/ema-committee-recommends-teclistamab-plus-daratumumab-for-relapsed-or-refractory-multiple-myeloma/">EMA committee recommends teclistamab plus daratumumab for relapsed or refractory multiple myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/ema-committee-recommends-teclistamab-plus-daratumumab-for-relapsed-or-refractory-multiple-myeloma/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>MPE joins patient organisations call for stronger patient voice in EU health technology assessments</title>
		<link>https://www.mpeurope.org/mpe-joins-patient-organisations-call-for-stronger-patient-voice-in-eu-health-technology-assessments/</link>
					<comments>https://www.mpeurope.org/mpe-joins-patient-organisations-call-for-stronger-patient-voice-in-eu-health-technology-assessments/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Wed, 01 Jul 2026 09:59:27 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=116418</guid>

					<description><![CDATA[<p>Myeloma Patients Europe has joined 14 other patient organisations members of the European Union Health Technology Assessment (EUHTA) stakeholder network to issue a joint statement on the publication of the first Joint Clinical Assessment (JCA) under the EU Health Technology Assessment Regulation (EUHTAR). The statement was coordinated by the European Patients Forum (EPF) and welcomes&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/mpe-joins-patient-organisations-call-for-stronger-patient-voice-in-eu-health-technology-assessments/">MPE joins patient organisations call for stronger patient voice in EU health technology assessments</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="116418" class="elementor elementor-116418" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-73b2c6c elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="73b2c6c" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-3aeb46a" data-id="3aeb46a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-4b30f02 elementor-widget elementor-widget-text-editor" data-id="4b30f02" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p class="font-claude-response-body break-words whitespace-normal">Myeloma Patients Europe has joined 14 other patient organisations members of the European Union Health Technology Assessment (EUHTA) stakeholder network to issue a joint statement on the publication of the first Joint Clinical Assessment (JCA) under the EU Health Technology Assessment Regulation (EUHTAR).</p><p class="font-claude-response-body break-words whitespace-normal">The statement was coordinated by the European Patients Forum (EPF) and welcomes the progress made in engaging patients and carers in the process but makes clear that more needs to be done to ensure the patient voice is meaningfully reflected in how medicines are assessed across Europe.</p><p class="font-claude-response-body break-words whitespace-normal"><strong>What the organisations are calling for</strong></p><p class="font-claude-response-body break-words whitespace-normal">The joint statement sets out five key recommendations for improving patient and carer involvement in the JCA process:</p><ul><li>Involving patients and carers from the earliest stages of assessment planning and scoping;</li><li>Strengthening the role of patient organisations in representing broader community perspectives;</li><li>Increasing transparency on how patient input influences assessments and final conclusions;</li><li>Improving the generation and use of evidence on outcomes that matter most to patients, such as quality of life and treatment burden; and</li><li>Ensuring that JCA findings are communicated in clear, accessible language and made available in all official EU languages.</li></ul>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-c6cbf5d elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="c6cbf5d" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-08f4f4e" data-id="08f4f4e" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-477c462 elementor-widget elementor-widget-text-editor" data-id="477c462" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p class="font-claude-response-body break-words whitespace-normal"><strong>MPE&#8217;s commitment</strong></p><p class="font-claude-response-body break-words whitespace-normal">As a signatory to the statement, MPE will continue to advocate for a EUHTA process that genuinely reflects the experiences and priorities of people living with myeloma and AL amyloidosis. Getting this right is important and we hope that the outcomes of these processes could accelerate access to treatments across Europe.</p><p class="font-claude-response-body break-words whitespace-normal">You can read the full statement here: <a class="underline underline underline-offset-2 decoration-1 decoration-current/40 hover:decoration-current focus:decoration-current" href="https://www.eu-patient.eu/news/latest-epf-news/2026/patient-organisations-welcome-publication-of-first-joint-clinical-assessment-under-eu-hta-regulation/">https://www.eu-patient.eu/news/latest-epf-news/2026/patient-organisations-welcome-publication-of-first-joint-clinical-assessment-under-eu-hta-regulation/</a></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/mpe-joins-patient-organisations-call-for-stronger-patient-voice-in-eu-health-technology-assessments/">MPE joins patient organisations call for stronger patient voice in EU health technology assessments</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/mpe-joins-patient-organisations-call-for-stronger-patient-voice-in-eu-health-technology-assessments/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>European Commission approves subcutaneous isatuximab for the treatment of multiple myeloma</title>
		<link>https://www.mpeurope.org/european-commission-approves-subcutaneous-isatuximab-for-the-treatment-of-multiple-myeloma/</link>
					<comments>https://www.mpeurope.org/european-commission-approves-subcutaneous-isatuximab-for-the-treatment-of-multiple-myeloma/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Tue, 09 Jun 2026 14:37:08 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=116169</guid>

					<description><![CDATA[<p>On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of isatuximab (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation of isatuximab. The newly approved subcutaneous formulation can be administered as a subcutaneous injection or using the CirCLIQ® on-body injector. This makes it the first&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/european-commission-approves-subcutaneous-isatuximab-for-the-treatment-of-multiple-myeloma/">European Commission approves subcutaneous isatuximab for the treatment of multiple myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="116169" class="elementor elementor-116169" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-0efdc71 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="0efdc71" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-5484b1b" data-id="5484b1b" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6a2a993 elementor-widget elementor-widget-text-editor" data-id="6a2a993" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>On 8 June 2026, the European Commission approved the subcutaneous (under the skin) formulation of <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/isatuximab/">isatuximab</a> (Sarclisa®) for use in all myeloma indications currently approved for the intravenous (IV) formulation of isatuximab.</p><p>The newly approved subcutaneous formulation can be administered as a subcutaneous injection or using the CirCLIQ® on-body injector. This makes it the first anticancer treatment approved in the European Union to be delivered via an on-body injector.</p><p>The CirCLIQ® on-body injector is a small, single use wearable device that automatically delivers isatuximab under the skin over a short period of time. The device is designed to allow treatment administration in outpatient settings and, where permitted, at home, potentially reducing the amount of time patients spend in hospital receiving treatment.</p><p>This approval follows the favourable recommendation issued by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) in March 2026, following the positive results of the <a href="https://ascopubs.org/doi/10.1200/JCO-25-00744" target="_blank" rel="noopener">IRAKLIA phase 3 study</a> and <a href="https://www.sanofi.com/assets/dotcom/pressreleases/2025/2025-06-03-12-26-42-3092736-en.pdf" target="_blank" rel="noopener">additional supporting studies</a>. The CHMP is the EMA committee responsible for assessing medicines and making recommendations about whether they should be approved for use.</p><p>Isatuximab is a type of targeted cancer treatment called a monoclonal antibody. It works by attaching to the CD38 protein found on the surface of myeloma cells, helping the immune system to identify and destroy these cancer cells.</p><p>Isatuximab is currently approved in the European Union in combination with:</p><ul><li><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/bortezomib/">bortezomib,</a> <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/lenalidomide/">lenalidomide</a> and dexamethasone (referred to as Isa-VRd) for transplant-eligible and transplant-ineligible newly diagnosed myeloma patients</li><li>pomalidomide and dexamethasone (referred to as Isa-Pd) for myeloma patients who have received at least two prior therapies, including treatment with lenalidomide and a proteasome inhibitor (such as bortezomib)</li><li><a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/carfilzomib/">carfilzomib</a> and dexamethasone (referred to as Isa-Kd) for myeloma patients who have received at least one prior therapy.</li></ul><p>Availability of the subcutaneous formulation will depend on the company’s marketing plans and, in some countries, further national assessments, pricing and reimbursement decisions.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/european-commission-approves-subcutaneous-isatuximab-for-the-treatment-of-multiple-myeloma/">European Commission approves subcutaneous isatuximab for the treatment of multiple myeloma</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/european-commission-approves-subcutaneous-isatuximab-for-the-treatment-of-multiple-myeloma/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>New ways to administer daratumumab and isatuximab get positive recommendations from EMA</title>
		<link>https://www.mpeurope.org/new-ways-to-administer-daratumumab-and-isatuximab-get-positive-recommendations-from-ema/</link>
					<comments>https://www.mpeurope.org/new-ways-to-administer-daratumumab-and-isatuximab-get-positive-recommendations-from-ema/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Fri, 10 Apr 2026 07:40:20 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=115771</guid>

					<description><![CDATA[<p>At the end of March, the Committee for Medicinal Products for Human Use (CHMP) announced two positive recommendations for new ways of administering the existing myeloma drugs daratumumab and isatuximab. Both drugs are monoclonal antibodies used in the treatment of myeloma. Both CHMP recommendations focus on subcutaneous injection, where a medication is injected into the&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/new-ways-to-administer-daratumumab-and-isatuximab-get-positive-recommendations-from-ema/">New ways to administer daratumumab and isatuximab get positive recommendations from EMA</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="115771" class="elementor elementor-115771" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-20d282d elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="20d282d" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-221a0bf" data-id="221a0bf" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-5949122 elementor-widget elementor-widget-text-editor" data-id="5949122" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>At the end of March, the Committee for Medicinal Products for Human Use (CHMP) announced two positive recommendations for new ways of administering the existing myeloma drugs <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/daratumumab/">daratumumab</a> and <a href="https://www.mpeurope.org/what-we-do/educational-resources/factsheets/isatuximab/">isatuximab.</a></p><p>Both drugs are monoclonal antibodies used in the treatment of myeloma. Both CHMP recommendations focus on subcutaneous injection, where a medication is injected into the fatty tissue layer between the skin and muscle.</p><p>The CHMP is the <a href="https://www.ema.europa.eu/en/homepage" target="_blank" rel="noopener">European Medicines Agency&#8217;s (EMA)</a> body responsible for evaluating, authorising, and monitoring human medicines in the EU. A positive recommendation from the CHMP still needs the official approval of the European Commission to be implemented, a process which typically takes around a few months.</p><p>The first CHMP decision enables subcutaneous daratumumab (Darzalex®) to be <a href="https://www.ema.europa.eu/en/events/committee-medicinal-products-human-use-chmp-23-26-march-2026" target="_blank" rel="noopener">administered at home</a> by patients or carers. The first four doses need to be administered in hospital by a patient or their carer under the supervision of their healthcare professional. After undergoing proper training, the fifth dose can be administered at home by a patient or carer if their healthcare professional considers that it is appropriate.</p><p>This applies to all current authorised uses of subcutaneous daratumumab.</p><p>For isatuximab (Sarclisa®), the CHMP recommended that the medicine could be administered as a <a href="https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-sarclisa-x-0000281242_en.pdf" target="_blank" rel="noopener"> subcutaneous injection and as a subcutaneous injection through an on-body injector</a>. The on-body injector is a device designed to deliver the medicine with the push of a button and would be the first myeloma medicine delivered this way. Both the subcutaneous injection and on-body injector delivery are done in hospital settings. Isatuximab is currently approved to be administered through intravenous infusion.</p><p>If approved, these recommendations will provide patients with more flexible options for the administration of daratumumab and isatuximab.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/new-ways-to-administer-daratumumab-and-isatuximab-get-positive-recommendations-from-ema/">New ways to administer daratumumab and isatuximab get positive recommendations from EMA</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/new-ways-to-administer-daratumumab-and-isatuximab-get-positive-recommendations-from-ema/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>AF3M recognised by French Prime Minister</title>
		<link>https://www.mpeurope.org/af3m-recognised-by-french-prime-minister/</link>
					<comments>https://www.mpeurope.org/af3m-recognised-by-french-prime-minister/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Fri, 27 Mar 2026 11:41:32 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=115554</guid>

					<description><![CDATA[<p>The French Prime Minister Recognizes AF3M as a Public Interest Association MPE member, The French Association of Myeloma Patients (AF3M) has been officially recognized as a Public Interest Association (Association Reconnue d’Utilité Publique) by decree dated 5 March 2026 and published in the French Republic Official Journal on 7 March 2026. This prestigious status is&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/af3m-recognised-by-french-prime-minister/">AF3M recognised by French Prime Minister</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="115554" class="elementor elementor-115554" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-470873a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="470873a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0a2ad54" data-id="0a2ad54" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6844a33 elementor-widget elementor-widget-text-editor" data-id="6844a33" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<h4>The French Prime Minister Recognizes AF3M as a Public Interest Association</h4>
<p>MPE member, The French Association of Myeloma Patients (AF3M) has been officially recognized as a Public Interest Association (Association Reconnue d’Utilité Publique) by decree dated 5 March 2026 and published in the French Republic Official Journal on 7 March 2026. This prestigious status is granted by the French Prime Minister, following a favourable opinion from the Minister of Health and a binding opinion from the Council of State (Conseil d’État). AF3M now joins a select group of only 61 French public interest associations in the health sector, of which just four focus specifically on cancer.<br><br>This is one of the highest distinctions a French non-profit can receive. It recognises that AF3M serves a mission of major public benefit and has a proven national impact, demonstrates strong governance, financial transparency and long-term stability. It also grants enhanced legal capacities, such as the ability to receive donations and legacies under favourable conditions. <br><br>Founded in 2007 by 29 myeloma patients and caregivers—with strong encouragement and early support from the French Myeloma Intergroup (IFM)—AF3M has grown steadily over the past two decades. In 2012, the association received official accreditation from the French Ministry of Health as a user association, enabling it to represent service users within hospital and public health bodies. Today, AF3M brings together more than 3,000 members and 200 volunteers across all regions of France.<br><br>Laurent Gillot, President of AF3M, and the entire Board of Directors, are confident that this recognition will further strengthen AF3M’s advocacy efforts and deepen its collaboration with Myeloma Patients Europe, thereby enhancing the impact of its long‑standing commitment to myeloma patients and caregivers.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/af3m-recognised-by-french-prime-minister/">AF3M recognised by French Prime Minister</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/af3m-recognised-by-french-prime-minister/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Launch of Myeloma Forward</title>
		<link>https://www.mpeurope.org/launch-of-myeloma-forward/</link>
					<comments>https://www.mpeurope.org/launch-of-myeloma-forward/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Thu, 26 Mar 2026 11:52:22 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=115542</guid>

					<description><![CDATA[<p>Launch of new myeloma patient support group, Myeloma Forward, in Northern Ireland On Monday, 23 March a new myeloma patient support group, called Myeloma Forward, launched in Belfast, Northern Ireland (NI). Myeloma Forward will hold bi-monthly meetings where speakers talk about some aspect of living with myeloma and share experiences and stories, providing peer support&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/launch-of-myeloma-forward/">Launch of Myeloma Forward</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="115542" class="elementor elementor-115542" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-7e5aea0 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="7e5aea0" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b573bf8" data-id="b573bf8" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-bc42165 elementor-widget elementor-widget-image" data-id="bc42165" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img fetchpriority="high" decoding="async" width="768" height="576" src="https://www.mpeurope.org/wp-content/uploads/2026/03/Myeloma-forward-768x576.jpg" class="attachment-medium_large size-medium_large wp-image-115544" alt="Myeloma forward" srcset="https://www.mpeurope.org/wp-content/uploads/2026/03/Myeloma-forward-768x576.jpg 768w, https://www.mpeurope.org/wp-content/uploads/2026/03/Myeloma-forward-300x225.jpg 300w, https://www.mpeurope.org/wp-content/uploads/2026/03/Myeloma-forward-1024x768.jpg 1024w, https://www.mpeurope.org/wp-content/uploads/2026/03/Myeloma-forward-1536x1152.jpg 1536w, https://www.mpeurope.org/wp-content/uploads/2026/03/Myeloma-forward-2048x1536.jpg 2048w" sizes="(max-width: 768px) 100vw, 768px" />															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-470873a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="470873a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0a2ad54" data-id="0a2ad54" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6844a33 elementor-widget elementor-widget-text-editor" data-id="6844a33" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<h4><strong>Launch of new myeloma patient support group, Myeloma Forward, in Northern Ireland</strong></h4><p>On Monday, 23 March a new myeloma patient support group, called Myeloma Forward, launched in Belfast, Northern Ireland (NI).</p><p>Myeloma Forward will hold bi-monthly meetings where speakers talk about some aspect of living with myeloma and share experiences and stories, providing peer support and peer advocacy.</p><p>The launch event was held in the NI Assembly, Stormont, Belfast and was attended by myeloma patients and their families, healthcare professionals, patient advocacy groups including MPE and Myeloma UK, research organisations and importantly, members of the NI assembly (also known as MLAs). The event was hosted by Michelle McIlveen MLA, following outreach and engagement by a Myeloma Forward patient in her constituency.</p><p>As well as launching Myeloma Forward, the event was designed to raise awareness of myeloma, the issue of late diagnosis and the importance of access to clinical trials and new treatments. The first part of the event was an informal “drop-in” session, with tea, coffee (and scones!), where MLAs could speak with attendees and hear about myeloma and these important issues.</p><p>Participants also heard from a range of speakers, including the Chair of the NI Assembly Health Committee, Philip McGuigan MLA; Dr Sarah Lawless, a haematologist in Belfast; three myeloma patients, including Bronagh Scott who organised the event and MPE co-CEO Kate Morgan.</p><p>Finally, attendees heard that the symbol that represents Myeloma Forward is the South African blood lily. They chose this flower, not only because of the name, but as a symbol of growth and strength. The launch event was a great success, with many attendees and great dialogue about the topics important to the myeloma community. MPE looks forward to seeing the development of Myeloma Forward and working with them in the coming years!</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/launch-of-myeloma-forward/">Launch of Myeloma Forward</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/launch-of-myeloma-forward/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>MPE visits plasma donation centre</title>
		<link>https://www.mpeurope.org/mpe-visits-plasma-donation-centre/</link>
					<comments>https://www.mpeurope.org/mpe-visits-plasma-donation-centre/#respond</comments>
		
		<dc:creator><![CDATA[Adam Davenport]]></dc:creator>
		<pubDate>Mon, 23 Mar 2026 14:26:28 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=114818</guid>

					<description><![CDATA[<p>MPE team members Kate Morgan (Co-CEO) and Barbara Leonardi (President) visited a private plasma donation centre in Vienna, Austria. Plasma donations are needed from people to produce immunoglobulin replacement therapy (you might hear it called IVIG) which is used in myeloma to reduce the risk of infection. It is of interest to MPE because myeloma&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/mpe-visits-plasma-donation-centre/">MPE visits plasma donation centre</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="114818" class="elementor elementor-114818" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-7e5aea0 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="7e5aea0" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-b573bf8" data-id="b573bf8" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-bc42165 elementor-widget elementor-widget-image" data-id="bc42165" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
															<img decoding="async" width="768" height="487" src="https://www.mpeurope.org/wp-content/uploads/2026/03/Group-photo-Day-1-e1774277533717-768x487.jpg" class="attachment-medium_large size-medium_large wp-image-115505" alt="Group photo Day 1" srcset="https://www.mpeurope.org/wp-content/uploads/2026/03/Group-photo-Day-1-e1774277533717-768x487.jpg 768w, https://www.mpeurope.org/wp-content/uploads/2026/03/Group-photo-Day-1-e1774277533717-300x190.jpg 300w, https://www.mpeurope.org/wp-content/uploads/2026/03/Group-photo-Day-1-e1774277533717-1024x650.jpg 1024w, https://www.mpeurope.org/wp-content/uploads/2026/03/Group-photo-Day-1-e1774277533717.jpg 1248w" sizes="(max-width: 768px) 100vw, 768px" />															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-470873a elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="470873a" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-0a2ad54" data-id="0a2ad54" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-6844a33 elementor-widget elementor-widget-text-editor" data-id="6844a33" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>MPE team members Kate Morgan (Co-CEO) and Barbara Leonardi (President) visited a private plasma donation centre in Vienna, Austria.</p><p>Plasma donations are needed from people to produce immunoglobulin replacement therapy (you might hear it called IVIG) which is used in myeloma to reduce the risk of infection. It is of interest to MPE because myeloma and its treatments affect the immune system.</p><h4><b>What is plasma?</b></h4><p>Plasma forms the liquid part of the human blood, which carries our white blood cells, red blood cells and platelets around the body. It is light yellow in colour, once the other blood cells are removed. Around 7% of plasma is made up of proteins such as immunoglobulins (a type of antibody) which are important in fighting infections.</p><h4><strong>What happens during the plasma donation process?</strong></h4><p>Austria is one of four EU countries that allows private plasma donation &#8211; where the donation centre is owned by a pharmaceutical company <span data-teams="true">(or third party vendor) </span>and people are paid to give their plasma. The other countries where this is allowed are Germany, Hungary and the Czech Republic. Plasma collected in these centres is not just used in that specific country, it is used to create products available across Europe.</p><p>Plasma is collected directly from a donor using a plasmapheresis machine. The process is similar to donating blood. A needle is placed into a vein in the arm, but the blood is passed through a machine that separates the plasma from the other blood cells. The remaining blood cells are then put back into the body. At this centre, the main way of collecting plasma was using a plasmapheresis machine. However, you can also collect it from whole blood samples (standard blood donations), sometimes called “recovered plasma”.</p><h4><strong>What happens once collected?</strong></h4><p>Once removed from the body, the collected plasma is “bagged” and frozen in a huge freezer (which in the daytime falls to under -40 degrees). During the visit, Kate and Barbara both got to see inside the huge freezer and can confirm how cold it was!</p><p>A highlight of the visit was seeing the number of people who had taken the time out of their busy day to donate their plasma. This ultimately leads to the creation of immunoglobulin replacement therapies, which are used in patients with myeloma, CLL and other immunodeficiencies.</p><p>Following the donation process, plasma is sent to another centre for a process called fractionation. This is where the different proteins in the plasma are separated out, enabling the creation of a range of products such as immunoglobulin replacement therapy which is used in myeloma.</p><h4><strong>What else did MPE learn?</strong></h4><p>Other interesting things MPE learnt from the visit include:</p><ul><li>In Austria, patients can donate their plasma up to 50 times a year. In Germany, this is 60 times and, in the USA, it is 100!</li><li>It takes about 60 &#8211; 90 minutes to donate your plasma. Although on your first visit it might take a bit longer.</li><li>Plasma and plasma donors undergo a series of rigorous and important checks, ensuring it is fit for use in humans.</li><li>Europe relies heavily on donations of plasma from the US – around 40% of plasma used in Europe comes from the USA.</li><li>There is a need to raise awareness of the importance of plasma donation to increase the resilience of supply in Europe.</li></ul><h6><span style="font-weight: bold; caret-color: rgba(0, 0, 0, 0); word-spacing: normal; color: #8e5569; font-size: 20px;">Further information</span></h6><p>If you would like to understand more about why immunoglobulins are important in myeloma, please read our <a href="https://www.mpeurope.org/what-we-do/educational-resources/qas/infection-risk-with-myeloma-and-myeloma-treatments/">infection materials</a>.</p><p>If you have any questions or comments, please email <a href="mailto:info@mpeurope.org">info@mpeurope.org</a></p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/mpe-visits-plasma-donation-centre/">MPE visits plasma donation centre</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/mpe-visits-plasma-donation-centre/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
		<item>
		<title>Join our webinar &#8220;The generics market in Europe and implications for cancer treatment and care&#8221;</title>
		<link>https://www.mpeurope.org/join-our-webinar-the-generics-market-in-europe-and-implications-for-cancer-treatment-and-care/</link>
					<comments>https://www.mpeurope.org/join-our-webinar-the-generics-market-in-europe-and-implications-for-cancer-treatment-and-care/#respond</comments>
		
		<dc:creator><![CDATA[Ana Vallejo]]></dc:creator>
		<pubDate>Thu, 05 Mar 2026 11:00:39 +0000</pubDate>
				<category><![CDATA[Access]]></category>
		<category><![CDATA[MPE]]></category>
		<guid isPermaLink="false">https://www.mpeurope.org/?p=115412</guid>

					<description><![CDATA[<p>Myeloma Patients Europe (MPE) will hold a webinar on the generics market in Europe and implications for cancer treatment and care on Monday 30th March from 17:00 – 18:30 CET. A generic medicine has the same active ingredient as a branded medicine and can be produced after the patent for the branded medicine expires. For&#8230;</p>
<p>The post <a href="https://www.mpeurope.org/join-our-webinar-the-generics-market-in-europe-and-implications-for-cancer-treatment-and-care/">Join our webinar &#8220;The generics market in Europe and implications for cancer treatment and care&#8221;</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></description>
										<content:encoded><![CDATA[		<div data-elementor-type="wp-post" data-elementor-id="115412" class="elementor elementor-115412" data-elementor-post-type="post">
						<section class="elementor-section elementor-top-section elementor-element elementor-element-f58b4ff elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="f58b4ff" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-100 elementor-top-column elementor-element elementor-element-fa6b94a" data-id="fa6b94a" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-0d04f93 elementor-widget elementor-widget-text-editor" data-id="0d04f93" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p>Myeloma Patients Europe (MPE) will hold a webinar on <strong>the generics market in Europe and implications for cancer treatment and care on Monday 30th March from 17:00 – 18:30 CET. </strong></p><p><span data-contrast="none">A generic medicine has the same active ingredient as a branded medicine and can be produced after the patent for the branded medicine expires. For example, Revlimid, a “backbone” treatment in myeloma, recently became generic and is marketed by a range of companies under the generic name lenalidomide. Generic medicines are often a lot cheaper than the branded product.</span><span data-ccp-props="{&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559738&quot;:120,&quot;335559739&quot;:120,&quot;335559740&quot;:240}"> </span></p><p><span data-contrast="none">Generics offer opportunities for cost savings for public budgets and increased access to treatments for patients. At the same time, generics face a lot of challenges such as intense price competition between companies, which can lead manufacturers to withdraw products, or supply chain vulnerabilities. </span><span data-ccp-props="{&quot;201341983&quot;:0,&quot;335551550&quot;:1,&quot;335551620&quot;:1,&quot;335559738&quot;:120,&quot;335559739&quot;:120,&quot;335559740&quot;:240}"> </span></p><p>This webinar will give the audience a lay introduction into generics and the generics market in Europe. This will be followed by <strong>three case studies</strong> presented by patient organisations with a focus in Central and Eastern Europe (CEE) which will focus on challenges and opportunities accessing generics from the patient point of view. The webinar will close with a <strong>panel discussion</strong> with the presenters on opportunities and challenges in the access of generic medication. During this panel discussion, the audience will have the opportunity to ask questions to the panellists.</p>								</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-4102354 elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="4102354" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-2626308" data-id="2626308" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-c0005db elementor-widget elementor-widget-text-editor" data-id="c0005db" data-element_type="widget" data-e-type="widget" data-widget_type="text-editor.default">
				<div class="elementor-widget-container">
									<p> </p><ul><li><strong>How does the generics market operate in Europe? </strong>Radluca Radu, Associate Director, Pharmaceutical Policy, Medicines for Europe. </li></ul><ul><li><strong>Industry perspective on challenges and opportunities in access to generics. </strong>Arnaud Maheas, Chair of the Generic Market Access Committee at Medicines for Europe &amp; Head Global Policy and Public Affairs Europe, Sandoz.</li></ul><ul><li><strong>Case study: Access to generic medicines in Poland. </strong>Carita Foundation, Poland.</li></ul><ul><li><strong>Case study: Patient advocacy and generics in Croatia and Bosnia. </strong>Mira Armour, Chief Executive, MijelomCRO.</li></ul><ul><li><strong>Presentation: Case study: Advocacy and access to generics in Chronic Myeloid Leukaemia (CML) in CEE. </strong>Jelena Cugurovic, Chair of the CML Advocates Network Steering Committee and CML Association of Serbia.</li></ul>								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-50 elementor-top-column elementor-element elementor-element-f235d9d" data-id="f235d9d" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-83a7d91 elementor-widget elementor-widget-image" data-id="83a7d91" data-element_type="widget" data-e-type="widget" data-widget_type="image.default">
				<div class="elementor-widget-container">
																<a href="https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic.png" data-elementor-open-lightbox="yes" data-elementor-lightbox-title="Webinar generic drugs graphic" data-e-action-hash="#elementor-action%3Aaction%3Dlightbox%26settings%3DeyJpZCI6MTE1NDI4LCJ1cmwiOiJodHRwczpcL1wvd3d3Lm1wZXVyb3BlLm9yZ1wvd3AtY29udGVudFwvdXBsb2Fkc1wvMjAyNlwvMDNcL1dlYmluYXJfZ2VuZXJpYy1kcnVncy1ncmFwaGljLnBuZyJ9">
							<img decoding="async" width="1024" height="1024" src="https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic-1024x1024.png" class="attachment-large size-large wp-image-115428" alt="Webinar generic drugs graphic" srcset="https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic-1024x1024.png 1024w, https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic-300x300.png 300w, https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic-150x150.png 150w, https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic-768x768.png 768w, https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic-500x500.png 500w, https://www.mpeurope.org/wp-content/uploads/2026/03/Webinar_generic-drugs-graphic.png 1080w" sizes="(max-width: 1024px) 100vw, 1024px" />								</a>
															</div>
				</div>
					</div>
		</div>
					</div>
		</section>
				<section class="elementor-section elementor-top-section elementor-element elementor-element-ac2e17f elementor-section-boxed elementor-section-height-default elementor-section-height-default" data-id="ac2e17f" data-element_type="section" data-e-type="section">
						<div class="elementor-container elementor-column-gap-default">
					<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-36a32cf" data-id="36a32cf" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
				<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-6ae20dd" data-id="6ae20dd" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap elementor-element-populated">
						<div class="elementor-element elementor-element-973c7ed elementor-widget elementor-widget-spacer" data-id="973c7ed" data-element_type="widget" data-e-type="widget" data-widget_type="spacer.default">
				<div class="elementor-widget-container">
							<div class="elementor-spacer">
			<div class="elementor-spacer-inner"></div>
		</div>
						</div>
				</div>
				<div class="elementor-element elementor-element-1f27cf3 elementor-align-center elementor-widget__width-initial elementor-widget elementor-widget-button" data-id="1f27cf3" data-element_type="widget" data-e-type="widget" data-widget_type="button.default">
				<div class="elementor-widget-container">
									<div class="elementor-button-wrapper">
					<a class="elementor-button elementor-button-link elementor-size-sm" href="https://mpeurope-org.zoom.us/webinar/register/WN_nfhmvz5ZSSqgCL0_oxrkag" target="_blank">
						<span class="elementor-button-content-wrapper">
									<span class="elementor-button-text"> Register now!</span>
					</span>
					</a>
				</div>
								</div>
				</div>
					</div>
		</div>
				<div class="elementor-column elementor-col-33 elementor-top-column elementor-element elementor-element-aa34479" data-id="aa34479" data-element_type="column" data-e-type="column">
			<div class="elementor-widget-wrap">
							</div>
		</div>
					</div>
		</section>
				</div>
		<p>The post <a href="https://www.mpeurope.org/join-our-webinar-the-generics-market-in-europe-and-implications-for-cancer-treatment-and-care/">Join our webinar &#8220;The generics market in Europe and implications for cancer treatment and care&#8221;</a> appeared first on <a href="https://www.mpeurope.org">Myeloma Patients Europe</a>.</p>
]]></content:encoded>
					
					<wfw:commentRss>https://www.mpeurope.org/join-our-webinar-the-generics-market-in-europe-and-implications-for-cancer-treatment-and-care/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
			</item>
	</channel>
</rss>
